hotspot -WSS

hotspot

author：comprehensive 2025-09-29 21:24:18 - browse：91953

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： HPV vaccine, cervical cancer study delivers historic results

WSS

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Cardiologists urge adding sexual orientation, gender identity to health records

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

European regulators consider appeal over Amylyx ALS drug

Takeaways from AdvaMed, the largest medical devices conference

Medicare to cover more brain scans related to Alzheimer’s drugs

hotspot

hotspot

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Dana Farber says 6 studies to be retracted and 31 corrected

Hollywood unions extend contract negotiations for actors

There's an unseen cost to disruptive road

New air purifier tech could be key to improving indoor air quality

Takeaways from AdvaMed, the largest medical devices conference

As demand for Covid shots wanes, Moderna seeks its next success

European regulators consider appeal over Amylyx ALS drug

Hollywood unions extend contract negotiations for actors

Nick Jonas talks about managing diabetes along with his career

hotspot

Medicare drug price lawsuits could be good politics for Biden

Prior authorization reform is both possible and imperative

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Head of FDA's diagnostics center, who led through Covid, retires

Dog Aging Project founders on what lies ahead after losing funding

Cardiologists urge adding sexual orientation, gender identity to health records

hotspot

leisure time

hotspot

explore